Related references
Note: Only part of the references are listed.Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
Jonathan M. Kocarnik et al.
JAMA ONCOLOGY (2022)
Risk of Fracture During Androgen Deprivation Therapy Among Patients With Prostate Cancer: A Systematic Review and Meta-Analysis of Cohort Studies
Cheng Chih Wu et al.
FRONTIERS IN PHARMACOLOGY (2021)
Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline
Philip J. Saylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bone health in cancer: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2020)
Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group
Janet E. Brown et al.
JOURNAL OF BONE ONCOLOGY (2020)
Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study
William D. Leslie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
A brief history of FRAX
John A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2018)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2017)
Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer A Systematic Review and Meta-analysis
Shabbir M. H. Alibhai et al.
ANNALS OF INTERNAL MEDICINE (2017)
Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline
S. M. H. Alibhai et al.
CLINICAL ONCOLOGY (2017)
A systematic review of intervention thresholds based on FRAX A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation
John A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2016)
Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications
Yu-Hsuan Shao et al.
BJU INTERNATIONAL (2013)
Competing mortality and fracture risk assessment
W. D. Leslie et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Osteoporosis-related fracture case definitions for population-based administrative data
Lisa M. Lix et al.
BMC PUBLIC HEALTH (2012)
Fracture prediction and calibration of a Canadian FRAXA® tool: a population-based report from CaMos
L-A. Fraser et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Construction of a FRAXA® model for the assessment of fracture probability in Canada and implications for treatment
W. D. Leslie et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Independent Clinical Validation of a Canadian FRAX Tool: Fracture Prediction and Model Calibration
William D. Leslie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
The Association of Bone Mineral Density with Prostate Cancer Risk in the Osteoporotic Fractures in Men (MrOS) Study
Ghada N. Farhat et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Incidence and risk factors for low trauma fractures in men with prostate cancer
Henrik G. Ahlborg et al.
BONE (2008)
A reference standard for the description of osteoporosis
John A. Kanis et al.
BONE (2008)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Construction and validation of a population-based bone densitometry database
WD Leslie et al.
JOURNAL OF CLINICAL DENSITOMETRY (2005)
Skeletal fractures negatively correlate with overall survival in men with prostate cancer.
MG Oefelein et al.
JOURNAL OF UROLOGY (2002)
Share Paper
